arrow
I

Ilsa M. Coleman

university of washington seattle
H指数:62
被引数:1.6万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Patient-derived models of prostate cancer: Capturing tumour complexity from initiation to metastasis

患者来源的前列腺癌模型:从起始到转移捕捉肿瘤复杂性

2026-08-010
OAAI
Systematic analysis of hippo pathway signaling identifies TEAD1 as a transcriptional regulator of neuroendocrine prostate cancer

系统分析 Hippo 通路信号传导确定了 TEAD1 是神经内分泌前列腺癌的转录调控因子

2026-05-300
OAAI
Multiomic assessments of LNCaP and derived cell strains reveal determinants of prostate cancer pathobiology

多组学评估揭示了LNCaP及其衍生细胞系在前列腺癌病理生物学中的决定因素

2025-11-170
OA
Elucidating molecularly stratified single agent, and combination, therapeutic strategies targeting MCL1 for lethal prostate cancer

阐明靶向MCL1的分子分层单药及联合治疗策略,以治疗致命性前列腺癌

2025-10-080
OAAI
Novel Skp1 inhibitor has potent preclinical efficacy against castration-resistant prostate cancer

新型Skp1抑制剂对去势抵抗性前列腺癌具有显著的体外疗效。

2025-04-190
PRE
Crosstalk between bone metastatic cancer cells and sensory nerves in bone metastatic progression
2024-09-121
OAAI
Assessment of TROP2, CEACAM5 and DLL3 in metastatic prostate cancer: Expression landscape and molecular correlates
2024-05-173
OAAI
Tumor-derived biomarkers predict efficacy of B7H3 antibody-drug conjugate treatment in metastatic prostate cancer models

肿瘤衍生的生物标志物预测B7H3抗体-药物偶联物治疗转移性前列腺癌模型的疗效

2023-11-153
OAAI
Pharmacological NF-?B inhibition decreases cisplatin chemoresistance in muscle-invasive bladder cancer and reduces cisplatin-induced toxicities.
2023-09-208
OAAI
LSD1 promotes prostate cancer reprogramming by repressing TP53 signaling independently of its demethylase function
2023-08-088
OA
Inhibition of androgen receptor signaling in castrate resistant prostate cancer in association with inhibition of glycolysis by targeting hexokinase 2 activity with pyrrolopyrimidine-based small molecules
2023-06-020
PRE
Targeting advanced prostate cancer with STEAP1 chimeric antigen receptor T cell and tumor-localized IL-12 immunotherapy
2023-04-1138
OAAI